GIKLY - Grifols, S.A.
| Previous Close | 17.14 |
| Open | 17.14 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 17.14 - 17.14 |
| 52 Week Range | 12.60 - 17.14 |
| Volume | 357 |
| Avg. Volume | 155 |
| Market Cap | 19.966B |
| Beta (3Y Monthly) | 0.55 |
| PE Ratio (TTM) | 28.59 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.22 (1.29%) |
| Ex-Dividend Date | 2019-12-02 |
| 1y Target Est | N/A |
- PR Newswire
Grifols to present latest Alzheimer's clinical trial results
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial at the Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, Calif. (USA).
- Simply Wall St.
Is Grifols (BME:GRF) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- Moody's
Grifols World Wide Operations USA, Inc. -- Moody's affirms Grifols Ba3 CFR; outlook stable
Moody's Investors Service ("Moody's") has today affirmed the Ba3 corporate family rating (CFR), Ba3-PD probability of default rating (PDR), and B2 senior unsecured rating of Grifols S.A. (Grifols), a Spanish healthcare company primarily focused on human blood plasma-derived products and transfusion medicine. At the same time, Moody's has assigned a Ba2 rating to the proposed USD5.0 billion equivalent worth of senior bank facilities to be issued by Grifols, Grifols World Wide Operations Ltd., and Grifols Worldwide Operations USA, Inc., both wholly-owned subsidiaries of Grifols.
- Simply Wall St.
Is Grifols, S.A.'s (BME:GRF) ROE Of 12% Impressive?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Grifols SA (GRFS)
We can judge whether Grifols SA (NASDAQ:GRFS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]
- Simply Wall St.
Is Grifols, S.A. (BME:GRF) Worth €27.10 Based On Its Intrinsic Value?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Grifols, S.A...
- Simply Wall St.
Should Grifols (BME:GRF) Be Disappointed With Their 61% Profit?
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
- Simply Wall St.
Is Grifols, S.A.'s (BME:GRF) 1.2% Dividend Worth Your Time?
Is Grifols, S.A. (BME:GRF) a good dividend stock? How can we tell? Dividend paying companies with growing earnings can...
- Simply Wall St.
How Much Are Grifols, S.A. (BME:GRF) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Investor's Business Daily
This Pharma Stock Dodged A Broad Slide For Drugmakers — Here's Why
Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.
- Benzinga
The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
- Motley Fool
Is Rigel Pharmaceuticals a Buy?
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
- Simply Wall St.
Do Institutions Own Grifols, S.A. (BME:GRF) Shares?
Every investor in Grifols, S.A. (BME:GRF) should be aware of the most powerful shareholder groups. Insiders often own...
- Moody's
Grifols World Wide Operations USA, Inc. -- Moody's announces completion of a periodic review of ratings of Grifols S.A.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Grifols S.A. Paris, May 16, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Grifols S.A. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Motley FoolRigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
RIGL earnings call for the period ending March 31, 2019.
- Simply Wall St.
What Does Grifols, S.A.'s (BME:GRF) P/E Ratio Tell You?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Grifols, S.A.'s (BME:GRF) P/E ratio could help you assess the value on offer...
- Simply Wall St.
Grifols, S.A. (BME:GRF): What We Can Expect From This Growth Stock
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Grifols, S.A.'s (BME:GRF) earnings update in December 2018, the cons...
- Reuters
Spain's Grifols, China's Shanghai RAAS form strategic alliance
Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China. Under the agreement, the Catalan company will take a 26.2 percent stake in Shanghai RAAS in exchange for a stake of 45 percent (with 40 percent voting rights) in its U.S. division Grifols Diagnostic Solutions (GDS). Grifols said that no external financing was required to fund the transaction which is expected to close in the second half of 2019 pending regulatory approval.
Motley FoolRigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript
RIGL earnings call for the period ending December 31, 2018.
- Simply Wall St.
What To Know Before Buying Grifols, S.A. (BME:GRF) For Its Dividend
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Dividends play an important role in compounding Read More...
- Benzinga
Rigel Rises On European Marketing Agreement For Autoimmune Drug
Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...
- Simply Wall St.
A Note On Grifols, S.A.’s (BME:GRF) ROE and Debt To Equity
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
